STAT Plus: Bristol’s MS drug approval is good news for shareholders but patients will have to wait
A new multiple sclerosis medicine from Bristol Myers Squibb (BMY) was approved Thursday by the Food and Drug Administration — a decision that may end up helping Bristol shareholders first, before patients.
The newly approved drug, a once-daily pill to be sold under the brand name Zeposia, was listed on Bristol’s website as an approved medicine, although the company has not made an official announcement. Likewise, there has been no statement issued by the FDA, although Zeposia’s prescribing label is now publicly available.
Continue to STAT Plus to read the full story…
